AMPH vs WST
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. WST: Global leader in injectable drug containment and delivery systems serving biopharmaceutical and medical device manufacturers with primary packaging, drug delivery devices, and contract manufacturing.
Side-by-side fundamentals
| Metric | AMPH | WST | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.30 | $358.41 | |
| Market cap as of 2026-07-23 | $864M | $25.8B | |
| P/E as of 2026-07-23 | 10.90 | 47.55 | AMPH lower |
| PEG as of 2026-07-23 | -1.77 | 3.24 | AMPH lower |
| Net margin as of 2026-07-23 | +11.0% | +16.9% | WST higher |
| Gross margin as of 2026-07-23 | +47.3% | +36.3% | AMPH higher |
| Operating margin as of 2026-07-23 | +16.2% | +20.3% | WST higher |
| ROE as of 2026-07-23 | +10.2% | +17.9% | WST higher |
| ROA as of 2026-07-23 | +4.8% | +13.2% | WST higher |
| Debt / equity as of 2026-07-23 | 0.79 | 0.07 | WST lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.4% | +11.2% | WST higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +2.1% | AMPH higher |
| Dividend yield as of 2026-07-23 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.91 | 1.12 | |
| 1-year return as of 2026-07-22 close | -7.6% | +63.7% | WST higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.